Pacer Advisors Inc. Takes $6.34 Million Position in Theravance Biopharma, Inc. $TBPH

Pacer Advisors Inc. purchased a new position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 338,958 shares of the biopharmaceutical company’s stock, valued at approximately $6,342,000. Pacer Advisors Inc. owned approximately 0.67% of Theravance Biopharma at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. boosted its stake in Theravance Biopharma by 26.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock valued at $46,000 after acquiring an additional 515 shares during the last quarter. Tower Research Capital LLC TRC increased its position in shares of Theravance Biopharma by 18.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 781 shares during the last quarter. Creative Planning increased its position in shares of Theravance Biopharma by 6.7% in the 3rd quarter. Creative Planning now owns 13,450 shares of the biopharmaceutical company’s stock worth $196,000 after purchasing an additional 842 shares during the last quarter. State of Wyoming raised its stake in shares of Theravance Biopharma by 5.7% in the 2nd quarter. State of Wyoming now owns 18,928 shares of the biopharmaceutical company’s stock valued at $209,000 after purchasing an additional 1,019 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Theravance Biopharma by 6.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,747 shares of the biopharmaceutical company’s stock valued at $174,000 after purchasing an additional 1,020 shares in the last quarter. Institutional investors own 99.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Wall Street Zen cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. HC Wainwright boosted their price objective on Theravance Biopharma from $20.00 to $27.00 and gave the company a “buy” rating in a report on Monday, March 2nd. BTIG Research restated a “buy” rating and set a $21.00 price objective on shares of Theravance Biopharma in a research note on Friday, March 20th. TD Cowen increased their target price on Theravance Biopharma from $13.00 to $15.00 and gave the stock a “hold” rating in a report on Monday, March 23rd. Finally, Weiss Ratings lowered Theravance Biopharma from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, May 27th. Two analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $21.40.

Insider Transactions at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 13,314 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $16.39, for a total value of $218,216.46. Following the transaction, the senior vice president owned 232,457 shares of the company’s stock, valued at $3,809,970.23. This trade represents a 5.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 7.65% of the stock is owned by corporate insiders.

Theravance Biopharma Stock Performance

Shares of NASDAQ:TBPH opened at $16.58 on Monday. The company’s fifty day moving average is $16.50 and its two-hundred day moving average is $17.35. Theravance Biopharma, Inc. has a 1-year low of $10.44 and a 1-year high of $21.03. The stock has a market capitalization of $854.70 million, a price-to-earnings ratio of 7.54 and a beta of 0.17.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) EPS for the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. The business had revenue of $17.70 million during the quarter. Sell-side analysts expect that Theravance Biopharma, Inc. will post 1.54 EPS for the current fiscal year.

Theravance Biopharma Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.